{
    "ticker": "ELVN",
    "name": "Eleven Therapeutics",
    "description": "Eleven Therapeutics is a biotechnology company focused on developing transformative RNA-targeted therapies for cancer and other serious diseases. Founded in 2020, Eleven leverages its proprietary RNA-targeting platform to discover and develop innovative treatments that can address the underlying causes of diseases at the genetic level. The company's technology aims to improve the precision and efficacy of therapeutic interventions by enabling the selective modulation of RNA transcripts. Eleven Therapeutics is dedicated to advancing its pipeline of product candidates through preclinical and clinical development, with a vision to significantly enhance patient outcomes. The organization prides itself on its collaborative approach, working closely with academic institutions and industry partners to accelerate the development and commercialization of its therapies. With a strong focus on scientific excellence and patient-centric innovation, Eleven Therapeutics is committed to making a meaningful impact in the field of medicine and addressing unmet medical needs.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2020",
    "website": "https://www.eleventx.com",
    "ceo": "Mark Levin",
    "social_media": {
        "twitter": "https://twitter.com/ElevenThera",
        "linkedin": "https://www.linkedin.com/company/eleven-therapeutics/"
    },
    "investor_relations": "https://investors.eleventx.com",
    "key_executives": [
        {
            "name": "Mark Levin",
            "position": "CEO"
        },
        {
            "name": "David B. Dodd",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "RNA-targeted therapies"
            ]
        }
    ],
    "seo": {
        "meta_title": "Eleven Therapeutics | RNA-targeted Cancer Therapies",
        "meta_description": "Explore Eleven Therapeutics, a leader in RNA-targeted therapies for cancer and serious diseases. Learn about our innovative approaches and pipeline.",
        "keywords": [
            "Eleven Therapeutics",
            "Biotechnology",
            "RNA-targeted therapies",
            "Cancer treatments",
            "Pharmaceutical innovation"
        ]
    },
    "faq": [
        {
            "question": "What is Eleven Therapeutics known for?",
            "answer": "Eleven Therapeutics is known for developing RNA-targeted therapies for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Eleven Therapeutics?",
            "answer": "Mark Levin is the CEO of Eleven Therapeutics."
        },
        {
            "question": "Where is Eleven Therapeutics headquartered?",
            "answer": "Eleven Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What types of products does Eleven Therapeutics develop?",
            "answer": "Eleven Therapeutics focuses on RNA-targeted therapies."
        },
        {
            "question": "When was Eleven Therapeutics founded?",
            "answer": "Eleven Therapeutics was founded in 2020."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO",
        "ALNY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}